© 2008 The Associated Press
WASHINGTON — The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
The agency's panel of psychiatric drug advisers will meet Feb. 6 to assess Zyprexa Adhera, an injectable version of the company's best-selling drug, which accounted for a quarter of Lilly's sales last year.
FDA said it is particularly concerned about incidents of severe drowsiness among patients tested with the new formulation.
Zyprexa is currently available in pill form to treat schizophrenia and bipolar disorder. Sales grew 6 percent to $1.67 billion in the final quarter of last year.
Shares of Eli Lilly & Co. rose $1.03 to $55.57 in morning trading Tuesday.
No comments:
Post a Comment